EGFL7

Across TCGA pan-cancer cohorts, EGFL7 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated EGFL7 data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher EGFL7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EGFL7 expression acts as an unfavorable survival marker.

LIHC, UCEC, and LUSC are the cancer types where EGFL7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.134	0.783	<.001	30	view →
UCEC	OS	Median	II,III,IV	0.231	0.768	.023	12	view →
LUSC	OS	Median	III,IV	0.112	0.664	.003	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

EGFL7–LIHC (OS)

Open the LIHC breakdown →